Close Menu

dual-priming oligonucleotide

Seegene will manufacture reagents designed exclusively for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.

CHICAGO (GenomeWeb) — Seegene this week plans to submit its first molecular diagnostic test for US Food and Drug Administration clearance, an assay for herpes simplex virus I and II that uses the company's TOCE primer technology for multiplexed real-time PCR.

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

Seegene said this week that BioMérieux has licensed its DPO and TOCE technologies to develop multiplexed molecular tests for food safety.

NEW YORK (GenomeWeb News) – Seegene said today that BioMérieux has taken a license to its DPO and TOCE technologies for the development of multiplexed molecular tests for food safety.
Financial terms of the agreement were not disclosed.

Molecular diagnostics and assay technology developer Seegene said this week that it has added yet another multiplex PCR-based chemistry to its portfolio of nucleic acid amplification, detection, and quantification technologies.

Seegene and DuPont Nutrition & Health said today that they have inked an agreement to jointly develop highly multiplexed assays to detect foodborne pathogens by combining Seegene's real-time PCR and melt curve analysis technology with DuPont's benchtop BAX System.

Seegene in the coming week will unveil a new technology that enables highly multiplexed melt curve analysis on existing commercial real-time PCR instruments.

The partnership combines Seegene's Dual Priming Oligo multiplex PCR technology with Akonni's TruArray gel-drop microarray technology.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.